Browsing by author "Cunningham, David"
Now showing items 61-80 of 80
-
Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival.
Shah, MA; Cunningham, D; Metges, J-P; Van Cutsem, E; Wainberg, Z; et al.<h4>Background</h4>Matrix metalloproteinase-9 (MMP9) selectively cleaves extracellular matrix proteins contributing to tumor growth and an immunosuppressive microenvironment. This study evaluated andecaliximab (ADX), an ... -
Reduced genomic tumor heterogeneity after neoadjuvant chemotherapy is related to favorable outcome in patients with esophageal adenocarcinoma.
Obulkasim, A; Ylstra, B; van Essen, HF; Benner, C; Stenning, S; et al. (2016-07)Neoadjuvant chemo(radio)therapy followed by surgery is the standard of care for patients with locally advanced resectable esophageal adenocarcinoma (EAC). There is increasing evidence that drug resistance might be related ... -
Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial.
Gleeson, M; Hawkes, EA; Cunningham, D; Chadwick, N; Counsell, N; et al. (2016-11)We performed a subgroup analysis of the phase III UK National Cancer Research Institute R-CHOP-14 versus R-CHOP-21 (two- versus three-weekly rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) trial to ... -
Robotic Distal Pancreatectomy Yields Superior Outcomes Compared to Laparoscopic Technique: A Single Surgeon Experience of 123 Consecutive Cases.
Ding, H; Kawka, M; Gall, TMH; Wadsworth, C; Habib, N; et al. (MDPI, 2023-11-20)Technical limitations of laparoscopic distal pancreatectomy (LDP), in comparison to robotic distal pancreatectomy (RDP), may translate to high conversion rates and morbidity. LDP and RDP procedures performed between December ... -
Safety and efficacy of durvalumab with R-CHOP or R<sup>2</sup>-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial.
Nowakowski, GS; Willenbacher, W; Greil, R; Larsen, TS; Patel, K; et al. (2021-11-19)Patients with high-risk diffuse large B-cell lymphoma (DLBCL) have poor outcomes following first-line cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab (R-CHOP). Evidence shows chemotherapy and immune ... -
SARS-CoV-2 Vaccine Immunogenicity in Patients with Gastrointestinal Cancer Receiving Systemic Anti-Cancer Therapy.
Lau, DK; Aresu, M; Planche, T; Tran, A; Lazaro-Alcausi, R; et al. (OXFORD UNIV PRESS, 2022-11-07)INTRODUCTION: Patients with gastrointestinal (GI) cancers have an increased risk of serious complications and death from SARS-CoV-2 infection. The immunogenicity of vaccines in patients with GI cancers receiving anti-cancer ... -
SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer.
Robles-Zurita, J; Boyd, KA; Briggs, AH; Iveson, T; Kerr, RS; et al. (2018-11-13)Background The Short Course Oncology Therapy (SCOT) study is an international, multicentre, non-inferiority randomised controlled trial assessing the efficacy, toxicity, and cost-effectiveness of 3 months (3 M) versus the ... -
Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial.
Meyer, T; Fox, R; Ma, YT; Ross, PJ; James, MW; et al. (2017-08)Background Transarterial chemoembolisation (TACE) is the standard of care for patients with intermediate stage hepatocellular carcinoma, while the multikinase inhibitor sorafenib improves survival in patients with advanced ... -
Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial.
Chen, L-T; Siveke, JT; Wang-Gillam, A; Li, C-P; Bodoky, G; et al. (2018-12)Background In the phase 3 randomised NAPOLI-1 clinical study, a 45% increase in median overall survival (OS) was shown with liposomal irinotecan, 5-fluorouracil and leucovorin (nal-IRI+5-FU/LV) versus 5-FU/LV in patients ... -
Systemic Chemotherapy as Salvage Treatment for Locally Advanced Rectal Cancer Patients Who Fail to Respond to Standard Neoadjuvant Chemoradiotherapy.
Sclafani, F; Brown, G; Cunningham, D; Rao, S; Tekkis, P; et al. (2017-06)Background The potential of chemotherapy as salvage treatment after failure of neoadjuvant chemoradiotherapy for locally advanced rectal cancer (LARC) has never been explored. We conducted a single-center, retrospective ... -
Systemic therapy in elderly patients with advanced biliary tract cancer: Sub-analysis of ABC-02 and 10 other prospective studies.
McNamara, MG; Bridgewater, JA; Lopes, A; Wasan, H; Malka, D; et al. (AMER SOC CLINICAL ONCOLOGY, 2016-02-01) -
Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials.
McNamara, MG; Bridgewater, J; Lopes, A; Wasan, H; Malka, D; et al. (2017-04-12)Background Outcomes in younger (<40 years) and elderly (≥70 years) patients with advanced biliary cancer (ABC) receiving palliative chemotherapy are unclear. This study assessed outcomes in those receiving monotherapy or ... -
Targeting Angiogenic Pathways in Colorectal Cancer: Complexities, Challenges and Future Directions.
Khan, K; Cunningham, D; Chau, I (2017-01)Colorectal cancer (CRC) is one of the commonest cancers in the world. During the last decade, the development of targeted therapies has given cancer treatment a novel direction in management of metastatic CRC (mCRC) and ... -
Targeting deficient DNA damage repair in gastric cancer.
Young, K; Starling, N; Cunningham, D (2016-09)Introduction Over recent years our understanding of DNA damage repair has evolved leading to an expansion of therapies attempting to exploit DNA damage repair deficiencies across multiple solid tumours. Gastric cancer has ... -
The Association of Cancer Physicians responds to "Cancer drugs, survival, and ethics".
Dangoor, A; Joffe, J; Januszewski, A; Mansi, J; Cunningham, D; et al. (2016-12-05) -
The evolving immunotherapeutic landscape in advanced oesophagogastric cancer.
Flynn, M; Young, K; Cunningham, D; Starling, N (2018-01)Improvements in median overall survival in the advanced oesophagogastric (OG) setting have plateaued, underlining the need for improved therapeutic approaches in this patient population. Immunotherapeutics are inducing ... -
The results of local excision with or without postoperative adjuvant chemoradiotherapy for early rectal cancer among patients choosing to avoid radical surgery.
Balyasnikova, S; Read, J; Tait, D; Wotherspoon, A; Swift, I; et al. (2017-02)Aim The study aimed to establish the oncological outcome of patients who opted for close surveillance with or without adjuvant chemoradiotherapy rather than radical surgery after local excision (LE) of early rectal ... -
The selection process can improve the outcome in locally advanced and recurrent colorectal cancer: activity and results of a dedicated multidisciplinary colorectal cancer centre.
Kontovounisios, C; Tan, E; Pawa, N; Brown, G; Tait, D; et al. (2017-04)Aim There is wide disparity in the care of patients with multivisceral involvement of rectal cancer. The results are presented of treatment of advanced and recurrent colorectal cancer from a centre where a dedicated ... -
Thorium-227-Labeled Anti-CD22 Antibody (BAY 1862864) in Relapsed/Refractory CD22-Positive Non-Hodgkin Lymphoma: A First-in-Human, Phase I Study.
Lindén, O; Bates, AT; Cunningham, D; Hindorf, C; Larsson, E; et al. (2021-04-21)Background: BAY 1862864 is an α-particle emitting thorium-227-labeled CD22-targeting antibody. This first-in-human dose-escalation phase I study evaluated BAY 1862864 in patients with CD22-positive relapsed/refractory B ... -
Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial.
Middleton, G; Palmer, DH; Greenhalf, W; Ghaneh, P; Jackson, R; et al. (2017-04)Background Erlotinib is an EGFR tyrosine kinase inhibitor that has shown a significant but only marginally improved median overall survival when combined with gemcitabine in patients with locally advanced and metastatic ...